B
Beth Muir
Researcher at Harvard University
Publications - 12
Citations - 3821
Beth Muir is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Growth factor receptor. The author has an hindex of 12, co-authored 12 publications receiving 3685 citations.
Papers
More filters
Journal ArticleDOI
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen
Xiao Jun Ma,Zuncai Wang,Paula D. Ryan,Steven J. Isakoff,Anne Barmettler,Andrew P. Fuller,Beth Muir,Gayatry Mohapatra,Ranelle C. Salunga,J. Todd Tuggle,Yen Tran,Diem Tran,Ana Tassin,Paul Amon,Wilson Wang,Wei Wang,Edward Enright,Kimberly Stecker,Eden Estepa-Sabal,Barbara L. Smith,Jerry Younger,Ulysses J. Balis,James S. Michaelson,Atul K. Bhan,Karleen Habin,Thomas M. Baer,Joan S. Brugge,Daniel A. Haber,Mark G. Erlander,Dennis C. Sgroi +29 more
TL;DR: An expression signature predictive of disease-free survival was reduced to a two-gene ratio, HOXB13 versus IL17BR, which outperformed existing biomarkers and may be useful for identifying patients appropriate for alternative therapeutic regimens in early-stage breast cancer.
Journal ArticleDOI
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon
Michael Overholtzer,Jianmin Zhang,Gromoslaw A. Smolen,Beth Muir,Wenmei Li,Dennis C. Sgroi,Chu-Xia Deng,Joan S. Brugge,Daniel A. Haber +8 more
TL;DR: Observations point to a potential oncogenic role for YAP in 11q22-amplified human cancers, and suggest that this highly conserved signaling pathway identified in Drosophila regulates both cellular proliferation and apoptosis in mammalian epithelial cells.
Journal ArticleDOI
Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials
Daphne W. Bell,Thomas J. Lynch,Sara M. Haserlat,Patricia L. Harris,Ross A. Okimoto,Brian W. Brannigan,Dennis C. Sgroi,Beth Muir,Markus J. Riemenschneider,Renee Iacona,Annetta D. Krebs,David H. Johnson,Giuseppe Giaccone,Roy S. Herbst,Christian Manegold,Masahiro Fukuoka,Mark G. Kris,José Baselga,Judith S. Ochs,Daniel A. Haber +19 more
TL;DR: EGFR mutations and, to a lesser extent, amplification appear to identify distinct subsets of NSCLC with an increased response to gefitinib, and the combination of gefithinib with chemotherapy does not improve survival in patients with these molecular markers.
Journal ArticleDOI
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
Gromoslaw A. Smolen,Raffaella Sordella,Beth Muir,Gayatry Mohapatra,Anne Barmettler,Heidi Archibald,Woo J. Kim,Ross A. Okimoto,Daphne W. Bell,Dennis C. Sgroi,James G. Christensen,Jeffrey Settleman,Daniel A. Haber +12 more
TL;DR: It is shown that gastric cancer cells with high-level stable chromosomal amplification of the growth factor receptor MET are extraordinarily susceptible to the selective inhibitor PHA-665752, which may identify a subset of epithelial cancers that are uniquely sensitive to disruption of this pathway.
Journal ArticleDOI
The Spemann organizer gene, Goosecoid, promotes tumor metastasis
Kimberly A. Hartwell,Beth Muir,Ferenc Reinhardt,Anne E. Carpenter,Dennis C. Sgroi,Robert A. Weinberg +5 more
TL;DR: It is demonstrated that Goosecoid promotes tumor cell malignancy and suggested that other conserved organizer genes may function similarly in human cancer.